Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Lung Infection

Update on REMS-Required Testing During COVID-19 Pandemic

Diana Ernst, RPh

March 27, 2020

For patients suspected of having COVID-19, undergoing REMS-required testing to obtain a medication may put others at risk.

Lung Infection

FDA Issues Statement Regarding NSAID Use and COVID-19

Diana Ernst, RPh

March 25, 2020

The Food and Drug Administration has issued a statement regarding the use of nonsteroidal anti-inflammatory drugs in patients with coronavirus disease 2019.

Lung Infection

FDA Updates Policy to Increase COVID-19 Testing Capabilities

Diana Ernst, RPh

March 20, 2020

Similar to the action taken in New York State, states will be responsible for the tests developed and used by laboratories in their states.

Lung Infection

FDA: Thermo Fisher COVID-19 Test Gets Emergency Use Authorization

Diana Ernst, RPh

March 18, 2020

The FDA has issued an Emergency Use Authorization to Thermo Fisher for its TaqPath COVID-19 Combo Kit, a diagnostic test that detects nucleic acid from SARS-CoV-2, the virus that causes coronavirus disease 2019.

Lung Infection

FDA Takes Additional Action to Expedite Availability of COVID-19 Tests

Diana Ernst, RPh

March 16, 2020

The FDA has announced that it will not object to the New York State Department of Health (NYSDOH) authorizing certain laboratories in New York to start testing patients for coronavirus disease 2019 (COVID-19) once the tests have been validated.

Lung Infection

Pipeline: Investigational Therapies for COVID-19

Diana Ernst, RPh

March 13, 2020

Currently, there are no antivirals licensed by the FDA to treat patients with COVID-19.

Lung Infection

FDA, FTC Crack Down on Fraudulent COVID-19 “Treatments”

Diana Ernst, RPh

March 12, 2020

Warning letters issued by the FDA and the FTC have been sent to several companies selling fraudulent products claiming to treat or prevent COVID-19.

Lung Infection

CDC Updates Guidance on Evaluating, Testing for COVID-19 as More Tests Become Available

Diana Ernst, RPh

March 11, 2020

The Centers for Disease Control and Prevention has updated the guidance for evaluation of persons under investigation for coronavirus disease 2019, expanding the criteria to a wider group of symptomatic patients.

Asthma

FDA Strengthens Warning About Risk of Neuropsychiatric Events With Montelukast

Diana Ernst, RPh

March 10, 2020

The FDA recommends that montelukast only be used for allergic rhinitis in patients who have had an inadequate response or intolerance to alternative therapies.

Lung Infection

FDA Authorizes Emergency Use of Certain Respirators for HCPs During COVID-19 Outbreak

Diana Ernst, RPh

March 5, 2020

More respirators, including certain N95 masks, will be made available to healthcare personnel, according to the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC).

Next post in Lung Infection